7 September 2023
Latham & Watkins Advises Ascendis Pharma A/S in Its Royalty Funding Agreement With Royalty Pharma
Advising firms
Deal team
10 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Jekkie Kim Lead | Latham & Watkins LLP | Partner | Not stated | Not stated |
| Haim Zaltzman Lead | Latham & Watkins LLP | Partner | Not stated | Not stated |
| Mark Roeder Lead | Latham & Watkins LLP | Partner | Not stated | Not stated |
| John Williams Lead | Latham & Watkins LLP | Partner | Not stated | Not stated |
| Billy Wu | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Tess Bloom | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Tyler Israel | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Elizabeth Oh | Latham & Watkins LLP | Partner | finance | Not stated |
| Eric Cho | Latham & Watkins LLP | Partner | tax | Not stated |
| Sam Yang | Latham & Watkins LLP | Associate | tax | Not stated |
7 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 150m (US$150 million)
- What the figure measures
- Facility amount
- Client
- Ascendis Pharma A/SBorrower
- Counterparties
- Royalty Pharma plc (Lenders)